Tag: guangdong

  • Shein Targets US$1.7 Billion Hong Kong Listing After Shifting Focus to China

    Shein Targets US$1.7 Billion Hong Kong Listing After Shifting Focus to China

    Shein will debut on the Hong Kong stock exchange on Tuesday, seeking to raise US$1.7 billion after abandoning earlier plans to list in New York and London.

    The listing values the fast-fashion group at US$26.5 billion, down from its peak valuation of more than US$100 billion in 2022. That drop follows years of regulatory hurdles in the West and an extensive effort to secure approval from Chinese market authorities.

    Supply Chain Commitments and Regulatory Clearances

    Founded in Nanjing in 2012, Shein shifted its corporate headquarters to Singapore in late 2021 as part of an attempt to position itself as a global retail player. That strategy ran into resistance from Chinese regulators, including the China Securities Regulatory Commission, which reviews foreign-registered businesses with substantial domestic operations.

    Founder Sky Xu responded by taking direct charge of regulatory relations in China. Xu made a rare public appearance at a February business forum in Guangdong province, pledging a US$1.5 billion investment to expand the company’s supply chain network across the region.

    The company also opened a research and development centre in Nanjing. In its Hong Kong listing prospectus, Shein confirmed that mainland China remains the central anchor of its logistics network and accounts for nearly 80 per cent of its total workforce.

    Western Market Pressures Reshape Listing Strategy

    Attempts to secure listings in the United States and the United Kingdom unraveled under heightened political and regulatory scrutiny. US lawmakers pushed for supply chain audits under the Uyghur Forced Labor Prevention Act, while trade policy shifts eliminated the US$800 de minimis customs exemption that originally accelerated Shein’s cross-border parcel volumes. European authorities introduced comparable parcel handling charges.

    Former executive chairman Donald Tang stepped down ahead of the Hong Kong filing after his previous public remarks claiming American corporate values drew criticism from Chinese officials.

    For retailers across Asia, Shein’s pivot illustrates the limits of cross-border corporate restructuring when manufacturing remains concentrated in southern China. Regional e-commerce operators face a tighter compliance environment globally, leaving Hong Kong as the primary capital market for Chinese-rooted digital exporters.

    Trading begins on Tuesday on the Hong Kong exchange, where investors will test Shein’s revised pricing against slowing margins in overseas markets.

  • Chinese medicines drive Zhongzhi growth

    Chinese medicines drive Zhongzhi growth

    Zhongzhi Pharmaceutical Holdings, which operates a network of pharmacies in the Guangdong province of China, has reported strong sales and earnings growth.

    Zhongzhi develops, manufactures and sells Chinese patent medicines, herbal remedies and food products sold under the core brands of Zeus, Liumian and Caojinghua.

    In the six months to June, the group achieved sales of RMB347.3 million, an increase of 20.6 per cent on the same period last year. Sales of ‘modern’ herbal remedies rose 44.5 per cent as a result of the group’s effort to expand its distribution and marketing network.

    “The continuous growth in the PRC pharmaceutical industry has been driven by favourable demographic trends, continuing urbanisation, the overall economy’s healthy expansion, and income growth which encourage greater public health awareness and consumption of pharmaceutical products,” the company said in its half year report.

    “The demand on pharmaceutical products will remain high and the related consumer expenditure is expected to increase year by year, which is beneficial to the further growth and development of the group. As such, it is anticipated that stable sales growth of our own-branded products in the PRC will continue in the near future.”

    In the year ahead, the company plans to expand its pharmacy network in the Guangdong province, boost its distribution network and expand its production capacity at the same time as putting more resources into researching new products and brand awareness marketing.

    Zhongshan has been operating chain pharmacies in Zhongshan under the Zeus banner for the sale of pharmaceutical products since 2001. As at June 30 it had 201 self-operated chain pharmacies in Zhongshan, five more than last year. Pharmacy sales increased by 15.9 per cent to RMB171.5 million for the six months, contributing 49.4 per cent of the company’s total revenue.